COVID-19

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting and pharmacy's role amid the COVID-19 pandemic.

Regeneron’s REGN-COV2 met primary and key secondary end points in its phase 2/3 trial evaluating the drug in the COVID-19 outpatient setting.

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting, and pharmacy's role amid the COVID-19 pandemic.

CMS’ new plan will ensure coverage of COVID-19 vaccines with no out-of-pocket costs, while increasing the number of providers that will administer the vaccine.

Here's the coronavirus-related news from this week that you should know. 

For our first episode in the ThoughtSpot 2020 series, experts from AmerisourceBergen and Healthcare Ready discuss how to support marginalized communities amid pandemics and natural disasters.

Although the company has ended the ACTIV-3 clinical trial, researchers are continuing to pursue all other studies of bamlanivimab in COVID-19.

Investigators stressed that governments, public health officials, and other non-governmental organizations should aim to build trust in a COVID-19 vaccine.

Here's the coronavirus-related news from this week that you should know.

The combined landscape of flu and COVID-19 presents challenges to vaccine uptake.

Remdesivir (Veklury; Gilead) is the first and only fully FDA-approved treatment for COVID-19.

The new guidance provides clarification on requirements for pharmacy interns and technicians to administer childhood and COVID-vaccines, as well as COVID-19 tests.

CBD and its impacts on a protective peptide show that the cannabinoid may reduce lung inflammation and damage.

The partnership aligns with Operation Warp Speed’s goal to protect the most vulnerable to COVID-19.

Here's the coronavirus-related news from this week that you should know.

In an open letter, Pfizer Chairman and CEO wrote that safety and efficacy data for its COVID-19 vaccine candidate may be ready by the third week of November for FDA submission.

The study will determine whether certain approved therapies or investigational drugs warrant advancement into larger-scale clinical trials for COVID-19.

AstraZeneca's investigational long-acting antibody combination will advance into phase 3 trials.

Here's the roundup for this week's coronavirus-related news.

A new report from the National Academies of Sciences, Engineering, and Medicine include pharmacists in the priority group for receiving the COVID-19 vaccine when available.

Regeneron and Eli Lilly have both submitted applications seeking emergency use authorization for their investigational COVID-19 therapies.

MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Navigating the COVID-19 Treatment Landscape: Clinical Controversies Explained” on Tuesday, October 13, 2020 at 6 PM EDT.

Here's the coronavirus-related news from this week that you should know.

Moderna’s COVID-19 mRNA vaccine candidate appears to induce as strong an immune response in older adults as in younger adults, according to an interim analysis.

Members of the MJH Life Sciences COVID-19 Coalition weighed in on the latest pandemic information in a recent survey.